newsfilter
← Latest News
GlobeNewswire·

CymaBay Announces Proposed $150 Million Public Offering of Common Stock and Pre-Funded Warrants

NEWARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and other chronic diseases